Journals / Cukurova Medical Journal / 2019 / Cilt: 44 - Sayı: 3

Does dipyrone produce anxiolytic-like effects in mice?

Dipiron farelerde anksiyolitik-benzeri etkiler oluşturuyor mu?

Pages
866–874
Publication Date
2019-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discrepancies in experimental models and methodologies may be the reason of our results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Paracetamol has been shown to exert anxiolytic-like effects mediated by endocannabinoids via cannabinoid CB1 receptors.
📊
Key Findings & Data:Involvement of central structures to its effects are long under debate, whereas recent findings suggesting contribution of cannabinoid CB1 receptors to its antinociceptive effect support this argument.
💡
Conclusion & Impact:Discrepancies in experimental models and methodologies may be the reason of our results.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:dipiron · anksiyete · kannabinoid

Abstract

Purpose: Paracetamol has been shown to exert anxiolytic-like effects mediated by endocannabinoids via cannabinoid CB1 receptors. Dipyrone is an analgesic with similar effects to paracetamol rather than non-steroidal anti-inflammatory drugs. Involvement of central structures to its effects are long under debate, whereas recent findings suggesting contribution of cannabinoid CB1 receptors to its antinociceptive effect support this argument. Taken together, the purpose of this study was to investigate whether dipyrone possesses anxiolytic-like behavior; contribution of cannabinoid CB1 and CB2 receptors and TRPV1 receptors will be determined in case of observing any effect of dipyrone in anxiety tests.Material and Methods: Balb-c mice effects of dipyrone (150, 300, 600 mg/kg, i.p.) were assessed in three-chamber social interaction, open-field, elevated plus-maze and rota rod tests. The cannabinoid CB1 antagonist AM251 (1 mg/kg i.p.), the CB2 antagonist SR 144528 (1 mg/kg i.p.) and the TRPV1 antagonist capsazepine (3 mg/kg i.p.) were going to be administered before dipyrone injections if any effect of dipyrone occurs. Results: Dipyrone had no effect at any dose in behavioral tests (three-chamber social interaction, open-field, elevated plus-maze and rota rod tests). Therefore, dipyrone is not tested together with the cannabinoid CB1 and CB2 antagonists and the TRPV1 receptor antagonist.Conclusion: Unlike paracetamol, dipyrone did not possess anxiolytic-like effects in mice. Discrepancies in experimental models and methodologies may be the reason of our results.

Özet

Amaç: Yakın zamanda parasetamol’ün anksiyolitik-benzeri etkileri olduğu ve bu etkilerine kannabinoid CB1 reseptörlerinin aracılık ettiği gösterilmiştir. Etkilerinde santral sinir sisteminin rolü olduğu uzun zamandır düşünülen ve etkileri açısından non-steroid anti-inflamatuvar ilaçlardan çok parasetamol ile benzerlik gösteren bir analjezik olan dipiron’un da antinosiseptif etkisinde kannabinoid sistemin rolü olduğu belirtilmiştir. Bu verilerden yola çıkarak dipiron’un anksiyolitik etki gösterebileceği düşünüldü; varsa bu etkisinde kannabinoid ve TRPV1 reseptörlerinin katkısının araştırılması planlandı.Gereç ve Yöntem: Balb-c farelerde dipiron (150, 300, 600 mg/kg, i.p.) verildikten sonra üç odalı sosyallik ve sosyal yenilik testi, açık alan testi ve yükseltilmiş artı labirent testleri uygulanması, etki görülürse kannabinoid CB1 antagonisti AM251 (1 mg/kg i.p.), CB2 antagonisti SR 144528 (1 mg/kg i.p.) ve TRPV1 antagonisti kapsazepin (3 mg/kg i.p.) ile birlikte verilmesi düşünüldü. Bulgular: Dipiron herhangi bir dozunda davranış testlerinin (üç odalı sosyallik ve sosyal yenilik testi, açık alan testi ve yükseltilmiş artı labirent testi) hiçbirisinde etki göstermedi. Bu nedenle, dipiron ile birlikte kannabinoid CB1, CB2 ve TRPV1 reseptör antagonistlerinin birlikte uygulanacağı aşamaya geçilmedi.Sonuç: Parasetamol’den farklı olarak, dipiron farelerde anksiyolitik-benzeri etkilere yol açmamaktadır. Deneysel modeller ve ölçüm yöntemlerindeki farklılıklar bu bulgularımızın nedeni olabilir.

🔖

Cite This Article

TOPUZ, R. D., GÜNDÜZ, Ö., DÖKMECİ, D., KARADAĞ, Ç. H., ULUGÖL, A. (2019). Does dipyrone produce anxiolytic-like effects in mice?. Cukurova Medical Journal, Cilt: 44 - Sayı: 3, 866–874. https://ajindex.com/articles/56380

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J. 2014;31:115-20
  2. Schrot RJ, Hubbard JR. Cannabinoids: Medical implications. Ann Med. 2016;48:128-41
  3. Wright S, Guy G. Licensed cannabis-based medicines: Benefits and risks. In: Handbook of Cannabis (Eds Pertwee R ): New York: Oxford University Press. 2014; 373-92
  4. Ulugol A. Kannabinoidlerin klinikte kullanılışı ve terapötik hedefler. Türkiye Klinikleri Farmakoloji Özel Sayısı. 2018;6:42-50
  5. Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav R. 2017;76:56-66
  6. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol. 2004;15:21-7
  7. Akman H, Aksu F, Gultekin I, Ozbek H, Oral U, Doran F et al. A possible central antinociceptive effect of dipyrone in mice. Pharmacology. 1996;53:71-8
  8. Carlsson KH, Jurna I. The Role of Descending Inhibition in the Antinociceptive Effects of the Pyrazolone Derivatives, Metamizol (Dipyrone) and Aminophenazone (Pyramidon). N-S Arch Pharmacol. 1987;335:154-9
  9. Gencer A, Gunduz O, Ulugol A. Involvement of descending serotonergic and noradrenergic systems and their spinal receptor subtypes in the antinociceptive effect of dipyrone. Drug Res. 2015;65:645-9
  10. Yilmaz I, Ulugol A. The Effect of Nitric Oxide Synthase Inhibitors on the Development of Analgesic Tolerance to Dipyrone in Mice. Int J Neurosci. 2009;119:755-64
  11. Kiroglu OE, Demirkol K, Berktas F, Yegani AA, Kirpik A, Maytalman E et al. Dipyrone ameliorates behavioural changes induced by unpredictable chronic mild stress: gender differences. Clin Invest Med. 2016;39:14-20
  12. Dani M, Guindon J, Lambert C, Beaulieu P. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur J Pharmacol. 2007;573:214-5
  13. Ottani A, Ferraris E, Giuliani D, Mioni C, Bertolini A,Sternieri E et al. Effect of sumatriptan in different models of pain in rats. Eur J Pharmacol. 2004;497:181-6
  14. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008;139:190-200
  15. Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, et al. Novel bioactive metabolites of d